Details for Patent: 10,705,070
✉ Email this page to a colleague
Which drugs does patent 10,705,070 protect, and when does it expire?
Patent 10,705,070 protects FYARRO and is included in one NDA.
Summary for Patent: 10,705,070
| Title: | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| Abstract: | The present invention provides methods of assessing suitability of a pharmaceutical composition for medical use. The pharmaceutical composition comprises nanoparticles comprising rapamycin coated with albumin and a non-nanoparticle portion comprising albumin and rapamycin. |
| Inventor(s): | Peykov; Viktor (San Diego, CA), Foss; Willard (San Diego, CA), Pierce; Daniel W. (Belmont, CA), Desai; Neil P. (Pacific Palisades, CA) |
| Assignee: | Abraxis BioScience, LLC (Summit, NJ) |
| Application Number: | 16/277,265 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 10,705,070
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aadi | FYARRO | sirolimus | POWDER;INTRAVENOUS | 213312-001 | Nov 22, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
